

PERSONAL INFORMATION

Saskia de Wildt

WORK EXPERIENCE

-
- May 2016- Present **Pediatrician**
Erasmus MC (Netherlands)
research
- May 2016- Present **Professor of Clinical Pharmacology and pediatric intensivist**
Radboud University Medical Center (Netherlands)
Research Clinical Pharmacology (focus on Pediatrics)
Clinical duties as pediatrician-intensivist
- January 2010-April 2016 **Pediatric intensivist & clinical pharmacologist**
Erasmus MC Sophia Childrens Hospital, Rotterdam (Netherlands)

EDUCATION AND TRAINING

-
- 1993 **Master of Science (M.Sc. Medicine)**
University of Maastricht, NL (Netherlands)

ADDITIONAL INFORMATION

-
- Expertise** Expertise areas:
Pediatrics
Pediatric Pharmacology
Intensive care
Obstetric pharmacology
Pain
Sedation
Acute kidney injury
- Dr. de Wildt combines clinical work with research on personalized clinical pharmacology with a focus on special populations, i.e. children and intensive care patients.
- Her research aims to understand the impact and interplay of factors such as age, critical illness and genetics on drug disposition and effect, using ex vivo and in vivo human studies. For this aim several innovative study methods have been used, including micro dosing, transporter proteomics and population PK modelling.
- She is responsible for the Dutch Pediatric Formulary and its international affiliates, thereby contributing to optimal on- and off-label drug use in children.
- She is active in the board of national and international societies and Networks, including the Dutch Society of Clinical Pharmacology (NVKFB), COST Action UNGAP, Task-force in Europe for Drug Development for the Young (TEDDY) and Paediatric Clinical Research Infrastructure Network (PedCRIN), European Pediatric Translational Research Infrastructure (EPTRI) and Conect4Children (C4c). With these activities, in combination with her own clinical work and research, she is building towards the goal of effective and safe therapy for each patient
2. Academic education and degrees
Master of Science (M.Sc. Medicine), University of Maastricht, NL
Medical Doctor (M.D.), University of Maastricht, NL
Doctorate degree (Ph.D.), Erasmus Universiteit Rotterdam, NL
Thesis: Developmental aspects of midazolam metabolism

Dutch Board Registration Pediatrician, Erasmus MC Sophia Childrens Hospital, NL
American Board Registration Clinical Pharmacologist (American Board of Clinical Pharmacology)
Dutch Board Registration Clinical Pharmacologist (Dutch Society of Clinical Pharmacology and Biopharmaceutics)
Dutch Board Registration Pediatric Intensivist (Erasmus MC Sophia Childrens Hospital, NL)
Associate Professor (Erasmus MC, Rotterdam NL)

Publications

1. Leng C, Rings E, de Wildt SN, SCDV IJ. Pharmacological and Parenteral Nutrition-Based Interventions in Microvillus Inclusion Disease. *J Clin Med*. 2020 Dec 23;10(1):22 (Impact factor 5.7, Q1).
2. Xu GM, Zavalkoff S, de Wildt SN, Duffett M. Gender and Authorship in Pediatric Critical Care Randomized Control Trials. *Pediatr Crit Care Med*. 2020 Dec;21(12):1035-41 (Impact factor 2.8, Q1).
3. de Leeuw TG, der Zanden TV, Ravera S, Felisi M, Bonifazi D, Tibboel D, Ceci A, Kaguelidou F, de Wildt SN, On Behalf Of The Gapp C. Diagnosis and Treatment of Chronic Neuropathic and Mixed Pain in Children and Adolescents: Results of a Survey Study amongst Practitioners. *Children (Basel)*. 2020 Nov 2;7(11).
4. Schijvens AM, de Wildt SN, Cornelissen EAM, van Hesteren FHS, Schreuder MF, Ter Heine R. Low Bioavailability of Oral Tacrolimus Suspension in Pediatric Kidney Transplant Patients. *Clin Pharmacokinet*. 2020 Nov;59(11):1483-5 (Impact factor 4.7, Q1).
5. van Groen BD, van Duijn E, de Vries A, Mooij MG, Tibboel D, Vaes WHJ, de Wildt SN. Proof of Concept: First Pediatric [(14) C]microtracer Study to Create Metabolite Profiles of Midazolam. *Clin Pharmacol Ther*. 2020 Nov;108(5):1003-9 (Impact factor 6.3, Q1 top 5).
6. Bestebreurtje P, de Koning BAE, Roeleveld N, Knibbe CAJ, Tibboel D, van Groen B, van de Ven CP, Plotz FB, de Wildt SN. Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial. *Eur J Drug Metab Pharmacokinet*. 2020 Oct;45(5):635-43 (Impactfactor 1.9, Q3).
7. Bestebreurtje P, Roeleveld N, Knibbe CAJ, van Sorge AA, Plotz FB, de Wildt SN. Development and Stability Study of an Omeprazole Suppository for Infants. *Eur J Drug Metab Pharmacokinet*. 2020 Oct;45(5):627-33 (Impact factor 1.9, Q3).
8. Wilson CM, Li Q, Gaedigk R, Bi C, de Wildt SN, Leeder JS, Fridley BL. Ontogeny Related Changes in the Pediatric Liver Metabolome. *Front Pediatr*. 2020;8:549 (Impact factor 2.4, Q2).
9. Smeets NJL, Litjens CHC, van den Heuvel J, van Hove H, van den Broek P, Russel FGM, Koenderink JB, de Wildt SN. Completing the Enalaprilat Excretion Pathway-Renal Handling by the Proximal Tubule. *Pharmaceutics*. 2020 Sep 30;12(10):935 (Impact factor 4.8, Q1).
10. Verscheijden LFM, van Hattem AC, Pertijs J, de Jongh CA, Verdijk RM, Smeets B, Koenderink JB, Russel FGM, de Wildt SN. Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression. *Histochem Cell Biol*. 2020 Sep;154(3):265-73 (Impact factor 2.6, Q1 top 5).
11. Verscheijden LFM, van der Zanden TM, van Bussel LPM, de Hoop-Sommen M, Russel FGM, Johnson TN, de Wildt SN. Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation. *Clin Pharmacol Ther*. 2020 Apr 22;108(2):248-52 (Impact factor 6.3, Q1, top 5).
12. Hartman SJF, Orriens LB, Zwaag SM, Poel T, de Hoop M, de Wildt SN. External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. *Paediatr Drugs*. 2020 Aug;22(4):433-44 (Impact factor 1.8, Q2).
13. Smeets NJL, Schreuder MF, Dalinghaus M, Male C, Lagler FB, Walsh J, Laer S, de Wildt SN. Pharmacology of enalapril in children: a review. *Drug Discov Today*. 2020 Aug 21: (Impact factor 6.8, Q1).
14. van Groen BD, Allegaert K, Tibboel D, de Wildt SN. Innovative approaches and recent advances in the study of ontogeny of drug metabolism and transport. *Br J Clin Pharmacol*. 2020 Aug 26: (Impact factor 2.9, Q1).
15. Schijvens AM, de Wildt SN, Schreuder MF. Pharmacokinetics in children with chronic kidney disease. *Pediatr Nephrol*. 2020 Juli;35(7):1153-72 (Impact factor 2.8, Q1).
16. van Groen BD, Pilla Reddy V, Badee J, Olivares-Morales A, Johnson TN, Nicolai J, Annaert P, Smits A, de Wildt SN, Knibbe CAJ, de Zwart L. Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. *Clin Transl Sci*. 2020 Jul 23:

(Impact factor 4.0, Q1).

17. Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM. Physiologically-based pharmacokinetic models for children: Starting to reach maturation? *Pharmacol Ther.* 2020 Jul;211:107541 (Impact factor 9.4, Q1, IF>8).
18. de Winter BCM, de Hoog M, Vet NJ, Dunk-Craaijo JH, Koch BCP, de Wildt SN. Finger-prick blood sampling for therapeutic drug monitoring: be aware of skin contamination by nebulized drugs. *Ther Drug Monit.* 2020 Jun;42(3):512-3 (Impact factor 2.1, Q3).
19. van Groen BD, Krekels EHJ, Mooij MG, van Duijn E, Vaes WHJ, Windhorst AD, van Rosmalen J, Hartman SJF, Hendrikse NH, Koch BCP, Allegaert K, Tibboel D, Knibbe CAJ, de Wildt SN. The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. *Clin Pharmacol Ther.* 2020 May 13: (Impact factor 6.3, Q1, top 5).
20. van Groen BD, Bi C, Gaedigk R, Staggs VS, Tibboel D, de Wildt SN, Leeder JS. Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver. *Clin Transl Sci.* 2020 May;13(3):509-19 (Impact factor 4.0, Q1).
21. Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, Zhao W, De Cock P, de Wildt SN, Allegaert K, van den Anker J. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. *Eur J Pediatr.* 2020 May;179(5):839-47 (impact factor 2.2, Q2).
22. van der Zanden TM, de Hoog M, Windster JD, van Rosmalen J, van der Sijs IH, de Wildt SN. Does a Dose Calculator as an Add-On to a Web-Based Paediatric Formulary Reduce Calculation Errors in Paediatric Dosing? A Non-Randomized Controlled Study. *Paediatr Drugs.* 2020 Apr;22(2):229-39 (Impact factor 1.8, Q2).
23. Stillhart C, Vucicevic K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla CM, Matthys C, Miljus G, Mooij MG, Parrott N, Ungell AL, de Wildt SN, Orlu M, Klein S, Mullertz A. Impact of gastrointestinal physiology on drug absorption in special populations--An UNGAP review. *Eur J Pharm Sci.* 2020 Apr 30;147:105280 (Impact factor 3.5, Q2).
24. Winter DA, Joosse ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, Pharmacodynamics and Immunogenicity of Infliximab in Paediatric Inflammatory Bowel Disease; a Systematic Review and Revised Dosing Considerations. *J Pediatr Gastroenterol Nutr.* 2020 Feb 7;70(6):763-76 (Impact factor 3.0, Q1).

25. Matic M, de Hoogd S, de Wildt SN, Tibboel D, Knibbe CA, van Schaik RH. OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery. *Pharmacogenomics.* 2020 Feb;21(3):181-93 (Impact factor 2.3, Q3).
26. Vermeulen E, Karsenberg K, van der Lee JH, de Wildt SN. Involve Children and Parents in Clinical Studies. *Clin Transl Sci.* 2020 Jan;13(1):11-3 (Impact factor 4.0, Q1).
27. Vet NJ, de Winter BCM, Koninckx M, Boeschoten SA, Boehmer ALM, Verhallen JT, Plotz FB, Vaessen-Verberne AA, van der Nagel BCH, Knibbe CAJ, Buysse CMP, de Wildt SN, Koch BCP, de Hoog M. Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. *Clin Pharmacokinet.* 2020 Feb;59(2):257-64 (Impact factor 4.7, Q1).
28. Hartman SJF, Bruggemann RJ, Orriens L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature. *Clin Pharmacokinet.* 2020 Feb;59(2):173-205 (impact factor 4.7, Q1).
29. Hartman SJF, Zwieters AJM, van de Water NEC, van Rosmalen J, Struck J, Schulte J, Hartmann O, Pickkers P, Beunders R, Tibboel D, Schreuder MF, de Wildt SN. Proenkephalin as a new biomarker for pediatric acute kidney injury - reference values and performance in children under one year of age. *Clin Chem Lab Med.* 2020 Oct 25;58(11):1911-9 (Impact factor 2.9, Q1, top 5).
30. Kleiber N, Calvier E, Mooij MG, Krekels EHJ, Vaes WHJ, Tibboel D, Knibbe CAJ, de Wildt SN. Enteral Acetaminophen Bioavailability in Pediatric Intensive Care Patients Determined With an Oral Microtracer and Pharmacokinetic Modeling to Optimize Dosing. *Crit Care Med.* 2019 Dec;47(12):e975-e83 (Impact factor 7.0, Q1, top 5).
31. Cheung KWK, van Groen BD, Burckart GJ, Zhang L, de Wildt SN, Huang SM. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters. *J Clin Pharmacol.* 2019 Sep;59 Suppl 1:S56-s69 (Impact factor 2.9, Q2).
32. van Groen BD, Vaes WH, Park BK, Krekels EHJ, van Duijn E, Korgvee LT, Maruszak W, Gryniewicz G, Garner RC, Knibbe CAJ, Tibboel D, de Wildt SN, Turner MA. Dose-linearity of the

- pharmacokinetics of an intravenous [(14) C]midazolam microdose in children. *Br J Clin Pharmacol*. 2019 Oct;85(10):2332-40 (Impact factor 2.9, Q1).
33. Brussee JM, Krekels EHJ, Calvier EAM, Palic S, Rostami-Hodjegan A, Danhof M, Barrett JS, de Wildt SN, Knibbe CAJ. A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. *Aaps j*. 2019 Jun 27;21(5):81 (Impact factor 3.5, Q1).
34. Bajcetic M, de Wildt SN, Dalinghaus M, Breitschütz J, Klingmann I, Lagler FB, Keatley-Clarke A, Breur JM, Male C, Jovanovic I, Szatmari A, Ablonczy L, Burckhardt BB, Cawello W, Kleine K, Obarcanin E, Spatenkova L, Swoboda V, van der Meulen M, Wagner P, Walsh J, Laer S. Orodispersible minitables of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. *Contemp Clin Trials Commun*. 2019 Sep;15:100393 (Impact factor 2.3, Q2).
35. Diez CC, Khalil F, Makowski N, Schwender H, Jovanovic I, Dalinghaus M, Walsh J, van der Meulen M, Bajcetic M, de Wildt SN, Laer S. Pharmacotherapy in paediatric heart failure: a Delphi process. *Cardiol Young*. 2019 Jul;29(7):869-76 (Impact factor 0.9, Q2).
36. de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Della Pasqua O, Tibboel D, Ceci A, de Wildt SN. Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial. *Trials*. 2019 Jun 20;20(1):368. (Impact factor 2.3, Q3)
37. Verscheijden LFM, Koenderink JB, de Wildt SN, Russel FGM. Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. *PLoS Comput Biol*. 2019 Jun;15(6):e1007117 (Impact factor 4.4, Q1, top 5).
38. Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn A, Simons-Oosterhuis Y, Tibboel D, Samsom JN, Verdijk RM, Smeets B, Zhang L, Huang SM, Giacomini KM, de Wildt SN. A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. *Clin Pharmacol Ther*. 2019 Nov;106(5):1083-92 (Impact factor 6.3, Q1, top 5).
39. Hartman SJF, Boeddha NP, Ekinci E, Koch BCP, Donders R, Hazelzet JA, Driessen GJ, de Wildt SN. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis. *Eur J Clin Microbiol Infect Dis*. 2019 Jul;38(7):1255-60 (Impact factor 2.6, Q2).
40. Castro Diez C, Khalil F, Schwender H, Dalinghaus M, Jovanovic I, Makowski N, Male C, Bajcetic M, van der Meulen M, de Wildt SN, Ablonczy L, Szatmari A, Klingmann I, Walsh J, Laer S. Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey. *BMJ Paediatr Open*. 2019;3(1):e000365 (Impact factor 2.3, Q1).
41. Kaguelidou F, Le Roux E, Mangiarini L, Lundin R, de Leeuw TG, Della Pasqua O, Felisi M, Bonifazi D, Tibboel D, Ceci A, de Wildt SN, Alberti C. Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol. *BMJ Open*. 2019 Feb 20;9(2):e023296 (Impact factor 2.8, Q2).
42. Bandell RAM, Dekkers T, Semmekrot BA, de Wildt SN, Fleuren H, Warle-van Herwaarden MF, Fussenich P, Gerrits GP, Kramers C. Macrolide prescription in Dutch children: compliance with guidelines. *Eur J Clin Microbiol Infect Dis*. 2019 Apr;38(4):675-81 (Impact factor 2.9, Q2).
43. de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Pasqua OD, Tibboel D, Ceci A, de Wildt SN. Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial. *Trials*. 2019 Jan 15;20(1):49 (Impact factor 2.3, Q3).
44. Schijvens AM, van Hesteren FHS, Cornelissen EAM, Bootsma-Robroeks C, Bruggemann RJM, Burger DM, de Wildt SN, Schreuder MF, Ter Heine R. The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. *Pediatr Nephrol*. 2019 Mar;34(3):507-15 (Impact factor 2.8, Q2).
45. Ketharanathan N, Yamamoto Y, Rohlwink UK, Wildschut ED, Mathot RAA, de Lange ECM, de Wildt SN, Argent AC, Tibboel D, Figaji AA. Combining Brain Microdialysis and Translational Pharmacokinetic Modeling to Predict Drug Concentrations in Pediatric Severe Traumatic Brain Injury: The Next Step Toward Evidence-Based Pharmacotherapy? *J Neurotrauma*. 2019 Jan 1;36(1):111-7 (Impact factor 5.1, Q1).

46. Badee J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. *Clin Pharmacokinet*. 2019 Feb;58(2):189-211 (Impact factor 4.9, Q1).
47. Schijvens AM, Ter Heine R, de Wildt SN, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. *Pediatr Nephrol*. 2019 Mar;34(3):389-403 (Impact factor 2.8, Q2).
48. Voller S, Flint RB, Beggah F, Reiss I, Andriessen P, Zimmermann LJI, van den Anker JN, Liem KD, Koch BCP, de Wildt S, Knibbe CAJ, Simons SHP. Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. *J Clin Pharmacol*. 2019 Oct;59(10):1300-8 (Impact factor 2.9, Q2).
49. de Leeuw TG, de Wildt SN. Reply to Stamer, Ulrike; Stuber, Frank, regarding their comment 'Analgesic efficacy of dipyron children - Still an absence of evidence'. *Paediatr Anaesth*. 2018 Dec;28(12):1156 (Impact factor 2.4, Q2).
50. van Groen BD, van de Steeg E, Mooij MG, van Lipzig MMH, de Koning BAE, Verdijk RM, Wortelboer HM, Gaedigk R, Bi C, Leeder JS, van Schaik RHN, van Rosmalen J, Tibboel D, Vaes WH, de Wildt SN. Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants. *Eur J Pharm Sci*. 2018 Nov 1;124:217-27 (Impact factor 3.9, Q2).
51. Brussee JM, Yu H, Krekels EHJ, Palic S, Brill MJE, Barrett JS, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. *Pharm Res*. 2018 Jul 30;35(9):182 (Impact factor 3.5, Q2).
52. Baarslag MA, Ista E, de Leeuw T, van Rosmalen J, Tibboel D, van Dijk M, de Wildt SN. Clinically effective implementation of intravenous paracetamol as primary analgesia after major surgery in neonates and young infants. *Arch Dis Child*. 2018 Dec;103(12):1168-9 (Impact factor 3.8, Q1).
53. Kleiber N, van Rosmalen J, Tibboel D, de Wildt SN. Hemodynamic Tolerance to IV Clonidine Infusion in the PICU. *Pediatr Crit Care Med*. 2018 Aug;19(8):e409-e16 (Impact factor 3.3, Q1).
54. Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. *Clin Pharmacol Ther*. 2018 Nov;104(5):900-15 (Impact factor 6.8, Q1, top 5).
55. Brussee JM, Yu H, Krekels EHJ, de Roos B, Brill MJE, van den Anker JN, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ. First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. *CPT Pharmacometrics Syst Pharmacol*. 2018 Jun;7(6):374-83 (Impact factor 3.9, .
56. Barker CIS, Standing JF, Kelly LE, Hanly Faught L, Needham AC, Rieder MJ, de Wildt SN, Offringa M. Pharmacokinetic studies in children: recommendations for practice and research. *Arch Dis Child*. 2018 Jul;103(7):695-702 (Impact factor 3.8, Q1).
57. van der Vossen AC, van Nuland M, Ista EG, de Wildt SN, Hanff LM. Oral lorazepam can be substituted for intravenous midazolam when weaning paediatric intensive care patients off sedation. *Acta Paediatr*. 2018 Mar 23: (Impact factor 2.3, Q1).
58. de Leeuw TG, Dirckx M, de Wildt SN. Reply to Ziesenitz, Victoria; Erb Thomas; Trachsel, Daniel; van den Anker Johannes, regarding their comment "Safety of dipyron (metamizole) in children-what's the risk of agranulocytosis?". *Paediatr Anaesth*. 2018 Mar;28(3):305-6 (Impact factor 2.4, Q2).
59. de Leeuw TG, Dirckx M, Gonzalez Candel A, Scoones GP, Huygen F, de Wildt SN. The use of dipyron (metamizol) as an analgesic in children: what is the evidence? A review. *Paediatr Anaesth*. 2018 Mar;28(3):309 (Impact factor 2.4, Q2).
60. Slooff VD, van den Dungen DK, van Beusekom BS, Jessurun N, Ista E, Tibboel D, de Wildt SN. Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. *Pediatr Crit Care Med*. 2018 Feb;19:e112-e9 (Impact factor 3.3, Q1).
61. Boukkedid R, Abdou AY, Desselas E, Monegat M, de Leeuw TG, Avez-Couturier J, Dugue S, Mareau C, Charron B, Alberti C, Kaguelidou F. The research gap in chronic paediatric pain: A systematic review of randomised controlled trials. *Eur J Pain*. 2018 Feb;22(2):261-71 (Impact factor 3.2, Q2).
62. van der Meulen M, Dalinghaus M, Burch M, Szatmari A, Castro Diez C, Khalil F, Swoboda V, Breur J, Bajcetic M, Jovanovic I, Lagler FB, Klingmann I, Laeer S, de Wildt SN. Question 1: How

safe are ACE inhibitors for heart failure in children? Arch Dis Child. 2018 Jan;103(1):106-9 (Impact factor 3.8, Q1).

63. Brussee JM, Vet NJ, Krekels EHJ, Valkenburg AJ, Jacqz-Aigrain E, van Gerven JMA, Swart EL, van den Anker JN, Tibboel D, de Hoog M, de Wildt SN, Knibbe CAJ. Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. Br J Clin Pharmacol. 2018 Feb;84(2):358-68 (Impact factor 2.9, Q1).

64. Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Bruggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clin Pharmacokinet. 2018 Apr;57(4):475-89 (Impact factor 5.8, Q1 upper ten).

65. Grootens-Wiegers P, Visser EG, van Rossum AMC, van Waardhuizen CN, de Wildt SN, Sweep B, van den Broek JM, de Vries MC. Perspectives of adolescents on decision making about participation in a biobank study: a pilot study. BMJ Paediatr Open. 2017;1(1):e000111 (Impact factor N/A).

66. de Leeuw TG, Dirckx M, Gonzalez Candel A, Scoones GP, Huygen F, de Wildt SN. The use of dipyron (metamizol) as an analgesic in children: What is the evidence? A review. Paediatr Anaesth. 2017 Dec;27(12):1193-201 (Impact factor 2.2, Q2).

67. Turner MA, Attar S, de Wildt SN, Vassal G, Mangiarini L, Giaquinto C. Roles of Clinical Research Networks in Pediatric Drug Development. Clin Ther. 2017 Oct;39(10):1939-48 (Impact factor 2.6, Q2).

68. Matic M, Jongen JL, Elens L, de Wildt SN, Tibboel D, Sillevs Smitt PA, van Schaik RH. Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. Pharmacogenomics. 2017 Aug;18(12):1133-42 (Impact factor 2.9, Q2).

69. Matic M, van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RHN. Reply. Pain. 2017 Aug;158(8):1623 (letter, Impact factor 6.2, Q1).

70. Matic M, de Wildt SN, Tibboel D, van Schaik RHN. Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. Clin Chem. 2017 Jul;63(7):1204-13 (Impact factor 8, Q1 upper ten).

71. Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017 May;101(5):646-56 (Impact factor 6.3, Q1 top 5).

72. Mooij MG, van Duijn E, Knibbe CAJ, Allegaert K, Windhorst AD, van Rosmalen J, Hendrikse NH, Tibboel D, Vaes WHJ, de Wildt SN. Successful Use of [(14)C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. Clin Pharmacokinet. 2017 Oct;56(10):1185-95 (Impact factor 5.8, Q1 upper ten).

73. Kleiber N, Mathot RAA, Ahsman MJ, Wildschut ED, Tibboel D, de Wildt SN. Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration. Br J Clin Pharmacol. 2017 Jun;83(6):1227-39 (Impact factor 2.9, Q1).

74. van der Zanden TM, de Wildt SN, Liem Y, Offringa M, de Hoog M. Developing a paediatric drug formulary for the Netherlands. Arch Dis Child. 2017 Apr;102(4):357-61 (Impact factor 3.8, Q1).

75. Matic M, van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RH. Genetic variants associated with thermal pain sensitivity in a paediatric population. Pain. 2016 Nov;157(11):2476-82 (Impact factor 6.2, Q1 upper ten).

76. Vet NJ, de Wildt SN, Verlaat CW, Mooij MG, Tibboel D, de Hoog M, Buysse CM. Short-Term Health-Related Quality of Life of Critically Ill Children Following Daily Sedation Interruption. Pediatr Crit Care Med. 2016 Nov;17(11):e513-e20 (Impact factor 2.7, Q2).

77. Vet NJ, Kleiber N, Ista E, de Hoog M, de Wildt SN. Sedation in Critically Ill Children with Respiratory Failure. Front Pediatr. 2016;4:89 (Impact factor N/A).

78. Prytula AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, Mathot RA. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet. 2016 Sep;55(9):1129-43 (Impact factor 5.0, Q1).

79. Mooij MG, van de Steeg E, van Rosmalen J, Windster JD, de Koning BA, Vaes WH, van Groen BD, Tibboel D, Wortelboer HM, de Wildt SN. Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life. Drug Metab Dispos. 2016 Jul;44(7):1005-13 (Impact factor 3.2, Q2).

80. Kleiber N, Tromp K, Tibboel D, de Wildt SN. Trial Recruitment in the Pediatric Intensive Care: Ask Consent Before You Start?! *Crit Care Med*. 2016 May;44(5):e309-10 (Impact factor 6.3, Q1).
81. Matic M, de Wildt SN, Elens L, de Hoon JN, Annaert P, Tibboel D, van Schaik RH, Allegaert K. SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. *Ther Drug Monit*. 2016 Aug;38(4):487-92 (Impact factor 2.4, Q2).
82. Mooij MG, de Koning BE, Lindenbergh-Kortleve DJ, Simons-Oosterhuis Y, van Groen BD, Tibboel D, Samsom JN, de Wildt SN. Human Intestinal PEPT1 Transporter Expression and Localization in Preterm and Term Infants. *Drug Metab Dispos*. 2016 Jul;44(7):1014-9 (Impact factor 3.2, Q2).
83. Vet NJ, de Wildt SN, Tibboel D, de Hoog M. Striving for an effective but parsimonious use of sedation in pediatric intensive care. *Intensive Care Med*. 2016 Jun;42(6):1103-4 (Impact factor 7.2, Q1).
84. Burt T, Yoshida K, Lappin G, Vuong L, John C, de Wildt SN, Sugiyama Y, Rowland M. Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. *Clin Transl Sci*. 2016 Apr;9(2):74-88 (Impact factor 1.4, Q?).
85. Kleiber N, de Wildt SN, Cortina G, Clifford M, Ducruet T, Tibboel D, Millar J. Clonidine as a First-Line Sedative Agent After Neonatal Cardiac Surgery: Retrospective Cohort Study. *Pediatr Crit Care Med*. 2016 Apr;17(4):332-41 (Impact factor 2.3, Q1).
86. Kleiber N, de Wildt SN, Cortina G, Clifford M, van Rosmalen J, van Dijk M, Tibboel D, Millar J. A Comparative Analysis of Preemptive Versus Targeted Sedation on Cardiovascular Stability After High-Risk Cardiac Surgery in Infants. *Pediatr Crit Care Med*. 2016 Apr;17(4):321-31 (Impact factor 2.3, Q1).
87. Vet NJ, Brussee JM, de Hoog M, Mooij MG, Verlaat CW, Jerchel IS, van Schaik RH, Koch BC, Tibboel D, Knibbe CA, de Wildt SN. Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. *Am J Respir Crit Care Med*. 2016 Jul 1;194(1):58-66 (Impact factor 13, Q1).
88. Lock J, de Bekker-Grob EW, Urhan G, Peters M, Meijer K, Brons P, van der Meer FJ, Driessens MH, Collins PW, Fijnvandraat K, Leebeek FW, Cnossen MH. Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. *Haemophilia*. 2016 Jan;22(1):e1-e10 (Impact factor 2.6, Q2).
89. Vet NJ, de Wildt SN, Verlaat CW, Knibbe CA, Mooij MG, van Woensel JB, van Rosmalen J, Tibboel D, de Hoog M. A randomized controlled trial of daily sedation interruption in critically ill children. *Intensive Care Med*. 2016 Feb;42(2):233-44 (Impact factor 7.2, Q1).
90. Mooij MG, Nies AT, Knibbe CA, Schaeffeler E, Tibboel D, Schwab M, de Wildt SN. Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. *Clin Pharmacokinet*. 2016 May;55(5):507-24 (Impact factor 5.0, Q1 upper 10).
91. Franken LG, Andrews LM, Slooff VD, de Wildt SN, Koch BC. Intoxication of a Young Girl Reveals the Pitfalls of GHB Rapid Screening. *Ther Drug Monit*. 2016 Feb;38(1):1-3 (Impact factor .2, Q).
92. Oostenbrink R, de Wildt SN. Drug trials: Kids are no little adults and not all kids are the same. *J Clin Epidemiol*. 2016 Mar;71:111-2 (Impact factor 3.4, Q1).
93. Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, Kruij M, Gorkom BL, Peters M, de Wildt S, Leebeek F, Cnossen M, Mathot R, group O-Cs. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. *Haematologica*. 2016 Oct;101(10):1159-69 (Impact factor 5.9, Q1 upper 10).
94. Zwiers AJ, Cransberg K, de Rijke YB, van Rosmalen J, Tibboel D, de Wildt SN. Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Renal Injury Following Extracorporeal Membrane Oxygenation. *Pediatr Crit Care Med*. 2015 Sep;16(7):663-70 (Impact factor 2.4, Q1).
95. Turner MA, Mooij MG, Vaes WH, Windhorst AD, Hendrikse NH, Knibbe CA, Korgvee LT, Maruszak W, Gryniewicz G, Garner RC, Tibboel D, Park BK, de Wildt SN. Pediatric microdose and microtracer studies using ¹⁴C in Europe. *Clin Pharmacol Ther*. 2015 Sep;98(3):234-7 (Impact factor 7.9, Q1 upper 10).
96. Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN. Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. *Clin Pharmacol Ther*. 2015 Sep;98(3):266-87 (Impact factor 7.9, Q1 upper 10).
97. Tromp K, de Wildt SN. [Ethical aspects of clinical drug research in critically ill children]. *Ned Tijdschr Geneeskd*. 2015;159:A8824.

98. Zwiers AJ, de Wildt SN, van Rosmalen J, de Rijke YB, Buijs EA, Tibboel D, Cransberg K. Urinary neutrophil gelatinase-associated lipocalin identifies critically ill young children with acute kidney injury following intensive care admission: a prospective cohort study. *Crit Care*. 2015 Apr 21;19:181 (Impact factor 4.5, Q1).
99. Andrews LM, Riva N, de Winter BC, Hesselink DA, de Wildt SN, Cransberg K, van Gelder T. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. *Expert Opin Drug Metab Toxicol*. 2015 Jun;11(6):921-36 (Impact factor 2.8, Q2).
100. Zwiers AJ, de Wildt SN, de Rijke YB, Willemsen SP, Abdullahi NS, Tibboel D, Cransberg K. Reference intervals for renal injury biomarkers neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in young infants. *Clin Chem Lab Med*. 2015 Jul;53(8):1279-89 (Impact factor 2.9, Q1).
101. Kleiber N, Tromp K, Mooij MG, van de Vathorst S, Tibboel D, de Wildt SN. Ethics of drug research in the pediatric intensive care unit. *Paediatr Drugs*. 2015 Feb;17(1):43-53 (Impact factor 1.8, Q2).
102. Boerlage AA, Ista E, Duivenvoorden HJ, de Wildt SN, Tibboel D, van Dijk M. The COMFORT behaviour scale detects clinically meaningful effects of analgesic and sedative treatment. *Eur J Pain*. 2015 Apr;19(4):473-9 (Impact factor 3.2, Q2).
103. Zwiers AJ, H IJ, van Rosmalen J, Gischler SJ, de Wildt SN, Tibboel D, Cransberg K. CKD and hypertension during long-term follow-up in children and adolescents previously treated with extracorporeal membrane oxygenation. *Clin J Am Soc Nephrol*. 2014 Dec 5;9(12):2070-8 (Impact factor 5.3, Q1 upper 10).
104. Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, Spaans E, Fabriek BO, Sandman H, Grossouw D, Hanff LM, Janssen PJ, Koch BC, Tibboel D, de Wildt SN. Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. *Clin Pharmacokinet*. 2014 Nov;53(11):1045-51 (Impact factor 5.9, Q1 upper 10).
105. de Wildt SN, Tibboel D, Leeder JS. Drug metabolism for the paediatrician. *Arch Dis Child*. 2014 Dec;99(12):1137-42 (Impact factor 3.8, Q1).
106. Slooff VD, Spaans E, van Puijenbroek E, Jessurun N, van Beusekom BS, de Hoog M, Tibboel D, de Wildt SN. Adverse events of haloperidol for the treatment of delirium in critically ill children. *Intensive Care Med*. 2014 Oct;40(10):1602-3 (Impact factor 5.5, Q1).
107. Matic M, Simons SH, van Lingen RA, van Rosmalen J, Elens L, de Wildt SN, Tibboel D, van Schaik RH. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. *Pharmacogenomics*. 2014 Jul;15(10):1287-95 (Impact factor 3.4, Q1).
108. Zwiers AJ, Cransberg K, de Rijke YB, Willemsen SP, de Mol AC, Tibboel D, de Wildt SN. Reference ranges for serum beta-trace protein in neonates and children younger than 1 year of age. *Clin Chem Lab Med*. 2014 Dec;52(12):1815-21 (Impact factor 2.9, Q1).
109. Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN, Spaans E, van Goudoever JB, Tibboel D, Kim RB, de Wildt SN. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. *Drug Metab Dispos*. 2014 Aug;42(8):1268-74 (Impact factor 3.3, Q1).
110. Kapitein B, Biesmans RCG, van der Sijs H, de Wildt SN. Propylene Glycol-Related Delirium After Esmolol Infusion. *Ann Pharmacother*. 2014 Jul;48(7):940-2 (Impact factor 2.4, Q1).
111. Vet NJ, de Wildt SN, Verlaat CW, Knibbe CA, Mooij MG, Hop WC, van Rosmalen J, Tibboel D, de Hoog M. Daily interruption of sedation in critically ill children: study protocol for a randomized controlled trial. *Trials*. 2014 Feb 13;15:55 (Impact factor 2.2, Q3).
112. Zwiers AJ, Cransberg K, van Rosmalen J, Wildschut ED, Tibboel D, de Wildt SN. Loop diuretics are an independent risk factor for acute kidney injury in children on extracorporeal membrane oxygenation with pre-emptive continuous hemofiltration. *Intensive Care Med*. 2014 Apr;40(4):627-8 (Impact factor 7.2, Q1 upper 10).
113. Krekels EH, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M, Danhof M, Knibbe CA. Evidence-based morphine dosing for postoperative neonates and infants. *Clin Pharmacokinet*. 2014 Jun;53(6):553-63 (Impact factor 5.0, Q1 upper 10).
114. van Zelle L, Utens EM, de Wildt SN, Vet NJ, Tibboel D, Buysse C. Analgesia-sedation in PICU and neurological outcome: a secondary analysis of long-term neuropsychological follow-up in meningococcal septic shock survivors*. *Pediatr Crit Care Med*. 2014 Mar;15(3):189-96 (Impact factor 2.2, Q1).

115. Gijssen VM, van Schaik RH, Soldin OP, Soldin SJ, Nulman I, Koren G, de Wildt SN. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study. *Ther Drug Monit.* 2014 Apr;36(2):152-8 (Impact factor 2.2, Q2).
116. Kapitein B, van Saet AW, Golab HD, de Hoog M, de Wildt S, Tibboel D, Bogers AJ. Does pharmacotherapy influence the inflammatory responses during cardiopulmonary bypass in children? *J Cardiovasc Pharmacol.* 2014 Aug;64(2):191-7 (Impact factor 2.1, Q3).
117. Havenaar R, Anneveld B, Hanff LM, de Wildt SN, de Koning BA, Mooij MG, Lelieveld JP, Minekus M. In vitro gastrointestinal model (TIM) with predictive power, even for infants and children? *Int J Pharm.* 2013 Nov 30;457(1):327-32 (Impact factor 3.8, Q1).
118. Zwijs AJ, de Wildt SN, Hop WC, Dorresteijn EM, Gischler SJ, Tibboel D, Cransberg K. Acute kidney injury is a frequent complication in critically ill neonates receiving extracorporeal membrane oxygenation: a 14-year cohort study. *Crit Care.* 2013 Jul 24;17(4):R151 (Impact factor 4.7, Q1).
119. Gijssen VM, van Schaik RH, Elens L, Soldin OP, Soldin SJ, Koren G, de Wildt SN. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. *Pharmacogenomics.* 2013 Jul;14(9):1027-36 (Impact factor 3.9, Q1).
120. Vet NJ, Ista E, de Wildt SN, van Dijk M, Tibboel D, de Hoog M. Optimal sedation in pediatric intensive care patients: a systematic review. *Intensive Care Med.* 2013 Sep;39(9):1524-34 (Impact factor 5.5, Q1).
121. Knibbe CA, Tibboel D, de Wildt SN, de Hoog M, Tjoeng MM, Danhof M. [Individualized dosing guidelines for children]. *Ned Tijdschr Geneesk.* 2013;157(16):A4214.
122. Ince I, de Wildt SN, Wang C, Peeters MY, Burggraaf J, Jacqz-Aigrain E, van den Anker JN, Tibboel D, Danhof M, Knibbe CA. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. *Clin Pharmacokinet.* 2013 Jul;52(7):555-65 (Impact factor 6.1, Q1 upper 10).
123. Ince I, Knibbe CA, Danhof M, de Wildt SN. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. *Clin Pharmacokinet.* 2013 May;52(5):333-45 (Impact factor 6.1, Q1 upper 10).
124. Gijssen VM, Hesselink DA, Croes K, Koren G, de Wildt SN. Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review. *Pediatr Transplant.* 2013 May;17(3):205-15 (Impact factor 1.5, Q1 upper 10).
125. Ceelie I, de Wildt SN, van Dijk M, van den Berg MM, van den Bosch GE, Duivenvoorden HJ, de Leeuw TG, Mathot R, Knibbe CA, Tibboel D. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. *Jama.* 2013 Jan 9;309(2):149-54 (Impact factor 30, Q1 upper 10).
126. van Saet A, de Wildt SN, Knibbe CA, Bogers AD, Stolker RJ, Tibboel D. The effect of adult and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic parameters. *Curr Clin Pharmacol.* 2013 Nov;8(4):297-318 (Impact factor N/A).
127. Wildschut ED, de Wildt SN, Mathot RA, Reiss IK, Tibboel D, Van den Anker J. Effect of hypothermia and extracorporeal life support on drug disposition in neonates. *Semin Fetal Neonatal Med.* 2013 Feb;18(1):23-7 (Impact factor 3.5, Q1).
128. Gijssen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: a review. *Ann Transplant.* 2012 Apr-Jun;17(2):111-21 (Impact factor 0.8, Q4).
129. Buijs EA, Zwijs AJ, Ista E, Tibboel D, de Wildt SN. Biomarkers and clinical tools in critically ill children: are we heading toward tailored drug therapy? *Biomark Med.* 2012 Jun;6(3):239-57 (Impact factor 2.6, Q2).
130. Mooij MG, de Koning BA, Huijsman ML, de Wildt SN. Ontogeny of oral drug absorption processes in children. *Expert Opin Drug Metab Toxicol.* 2012 Oct;8(10):1293-303 (Impact factor 3.2, Q2).
131. Ince I, de Wildt SN, Peeters MY, Murry DJ, Tibboel D, Danhof M, Knibbe CA. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. *Ther Drug Monit.* 2012 Aug;34(4):381-9 (Impact factor 2.5, Q2).
132. de Wildt SN. Drug metabolism in pediatrics, pregnancy and lactation. *Curr Drug Metab.* 2012 Jul;13(6):693 (Impact factor 3.5, Q1).
133. Wildschut ED, Ahsman MJ, Houmes RJ, Pokorna P, de Wildt SN, Mathot RA, Tibboel D. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). *Curr Drug Metab.* 2012 Jul;13(6):767-77 (Impact factor 5.1, Q1).

134. Ceelie I, de Wildt SN, de Jong M, Ista E, Tibboel D, van Dijk M. Protocolized post-operative pain management in infants; do we stick to it? *Eur J Pain*. 2012 May;16(5):760-6 (Impact factor 3.8, Q1).
135. Cella M, Knibbe C, de Wildt SN, Van Gerven J, Danhof M, Della Pasqua O. Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. *Br J Clin Pharmacol*. 2012 Sep;74(3):525-35 (Impact factor 2.9, Q1).
136. Vet NJ, Verlaat CW, de Wildt SN, Tibboel D, de Hoog M. Daily interruption of sedation in critically ill children. *Pediatr Crit Care Med*. 2012 Jan;13(1):122; author reply -3 (Impact factor 2.8, Q1).
137. Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wildt SN. The status of paediatric medicines initiatives around the world--What has happened and what has not? *Eur J Clin Pharmacol*. 2012 Jan;68(1):1-10 (Impact factor 3.0, Q2).
138. Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of critical illness and inflammation on midazolam therapy in children. *Pediatr Crit Care Med*. 2012 Jan;13(1):e48-50 (Impact factor 2.8, Q1).
139. Van Saet A, De Wildt SN. Prevention of Low Cardiac Output Syndrome in children: where is the evidence? *Paediatr Anaesth*. 2011 Dec;21(12):1173-5 (Impact factor 2.1, Q2).
140. Vandervaart S, Berger H, Tam C, Goh YI, Gijsen VM, de Wildt SN, Taddio A, Koren G. The effect of distant reiki on pain in women after elective Caesarean section: a double-blinded randomised controlled trial. *BMJ Open*. 2011 Feb 26;1(1):e000021 (Impact factor N/A).
141. Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. *J Heart Lung Transplant*. 2011 Dec;30(12):1352-9 (Impact factor 4.3, Q1 upper 10).
142. Ahsman MJ, Tibboel D, Mathot RA, de Wildt SN. Sample collection, biobanking, and analysis. *Handb Exp Pharmacol*. 2011;205:203-17.
143. VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. *Ther Drug Monit*. 2011 Aug;33(4):425-32 (Impact factor 3.1, Q1).
144. de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. *Eur J Clin Pharmacol*. 2011 Dec;67(12):1231-41 (Impact factor 3.0, Q2).
145. de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. *Expert Opin Drug Metab Toxicol*. 2011 Aug;7(8):935-48 (Impact factor 3.4, Q2).
146. Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of inflammation on drug metabolism: a focus on pediatrics. *Drug Discov Today*. 2011 May;16(9-10):435-42 (Impact factor 6.6, Q1 upper 10).
147. Ceelie I, James LP, Gijsen V, Mathot RA, Ito S, Tesselaar CD, Tibboel D, Koren G, de Wildt SN. Acute liver failure after recommended doses of acetaminophen in patients with myopathies. *Crit Care Med*. 2011 Apr;39(4):678-82 (Impact factor 6.2, Q1 upper 10).
148. Ceelie I, van Dijk M, Bax NM, de Wildt SN, Tibboel D. Does minimal access major surgery in the newborn hurt less? An evaluation of cumulative opioid doses. *Eur J Pain*. 2011 Jul;15(6):615-20 (Impact factor 3.6, Q1).
149. Ceelie I, van der Starre C, Tibboel D, Stol K, Koren G, de Wildt SN. Evaluation of drug formularies for pediatric intensive care. *Pediatr Crit Care Med*. 2011 Jan;12(1):e14-9 (Impact factor 2.8, Q1).
150. Wildschut ED, Hanekamp MN, Vet NJ, Houmes RJ, Ahsman MJ, Mathot RA, de Wildt SN, Tibboel D. Feasibility of sedation and analgesia interruption following cannulation in neonates on extracorporeal membrane oxygenation. *Intensive Care Med*. 2010 Sep;36(9):1587-91 (Impact factor 5.2, Q1).
151. de Wildt SN, Kearns GL, Murry DJ, Koren G, van den Anker JN. Ontogeny of midazolam glucuronidation in preterm infants. *Eur J Clin Pharmacol*. 2010 Feb;66(2):165-70 (Impact factor 1.8, Q2).

152. vanderVaart S, Gijsen VM, de Wildt SN, Koren G. A systematic review of the therapeutic effects of Reiki. *J Altern Complement Med.* 2009 Nov;15(11):1157-69 (Impact factor 1.6, Q2).
153. van der Lee R, Ceelie I, de Wildt SN. Morphine-induced muscle rigidity in a term neonate. *Ann Pharmacother.* 2009 Oct;43(10):1724-6 (Impact factor 2.4, Q1).
154. de Wildt SN, Knibbe CA. Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. *Eur J Clin Pharmacol.* 2009 Aug;65(8):849-50; author reply 51-2 (Impact factor 1.8, Q2).
155. Gijsen VM, de Wildt SN, Ito S. Probability of rash related to gabapentin therapy in a child. *Ann Pharmacother.* 2009 Feb;43(2):387-9 (Impact factor 2.4, Q1).
156. de Wildt SN, Taguchi N, Koren G. Unintended pregnancy during radiotherapy for cancer. *Nat Clin Pract Oncol.* 2009 Mar;6(3):175-8 (Impact factor 9.1, Q1 upper 10).
157. Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. *Drug Discov Today.* 2009 Mar;14(5-6):316-20 (Impact factor 6.6, Q1 upper 10).
158. de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. *Drug Discov Today.* 2009 Jan;14(1-2):6-15 (Impact factor 6.6, Q1 upper 0).
159. de Wildt SN, Koren G. Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected]. *Paediatr Anaesth.* 2008 Mar;18(3):273-4; author's reply 5-6 (Impact factor 2.2, Q2).
160. de Wildt SN, Verzijden R, van den Anker JN, de Hoog M. Information technology cannot guarantee patient safety. *Bmj.* 2007 Apr 21;334(7598):851-2 (Impact factor 9.2, Q1 upper 10).
161. de Wildt SN, Berns MJ, van den Anker JN. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study. *Ther Drug Monit.* 2007 Apr;29(2):225-30 (Impact factor 2.4, Q1).
162. de Wildt SN, de Hoog M, Vinks AA, Joosten KF, van Dijk M, van den Anker JN. Pharmacodynamics of midazolam in pediatric intensive care patients. *Ther Drug Monit.* 2005 Feb;27(1):98-102 (Impact factor 3.0, Q1).
163. de Wildt SN, de Hoog M, Vinks AA, van der Giesen E, van den Anker JN. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. *Crit Care Med.* 2003 Jul;31(7):1952-8 (Impact factor 4.2, Q1 upper 10).
164. de Wildt SN, Kearns GL, Sie SD, Hop WC, van den Anker JN. Pharmacodynamics of intravenous and oral midazolam in preterm infants. *Clin Drug Investig.* 2003;23(1):27-38 (Impact factor 0.9, Q3).
165. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. *Br J Clin Pharmacol.* 2002 Apr;53(4):390-2 (Impact factor 2.9, Q1).
166. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. *Clin Pharmacol Ther.* 2001 Dec;70(6):525-31 (Impact factor 5.1, Q1 upper 10).
167. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. The CYP3A4*3 allele: is it really rare? *Clin Chem.* 2001 Jun;47(6):1104-6 (Impact factor 4.6, Q1 upper 10).
168. de Wildt SN, Kerkvliet KT, Wezenberg MG, Ottink S, Hop WC, Vulto AG, van Den Anker JN. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. *Ther Drug Monit.* 2001 Jun;23(3):250-4 (Impact factor 2.0, Q1).
169. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. *Clin Chem.* 2000 Nov;46(11):1834-6 (Impact factor 4.6, Q1 upper 10).
170. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. *Clin Pharmacokinet.* 1999 Dec;37(6):485-505 (Impact factor 5.1, Q1 upper 10).
171. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. *Clin Pharmacokinet.* 1999 Jun;36(6):439-52 (Impact factor 5.1, Q1 upper 10).
172. van den Anker JN, de Wildt SN. [Excessive terfenadine level due to drinking grapefruit juice]. *Ned Tijdschr Geneesk.* 1997 Oct 11;141(41):1976-8.
173. de Wildt SN, van den Anker JN. [Syncope with simultaneous use of terfenadine and itraconazole]. *Ned Tijdschr Geneesk.* 1997 Sep 6;141(36):1752-3.

174. Smith FG, Chan S, De Wildt SN. Effects of renal denervation on cardiovascular and renal responses to ACE inhibition in conscious lambs. *J Appl Physiol* (1985). 1997 Aug;83(2):414-9 (Impact factor 1.3, Q2).
175. de Wildt SN, Smith FG. Effects of the angiotensin converting enzyme (ACE) inhibitor, captopril, on the cardiovascular, endocrine, and renal responses to furosemide in conscious lambs. *Can J Physiol Pharmacol*. 1997 Apr;75(4):263-70 (Impact factor 1.3, Q2).
176. Smith FG, Strack AM, de Wildt SN. Renal nerves do not modulate the renal and endocrine responses to furosemide in conscious lambs. *Can J Physiol Pharmacol*. 1996 May;74(5):614-20 (Impact factor 1.3, Q2).

Projects

FUNDING (co-PI)

- 2020 Bill & Melinda Gates Foundation 610,000.--
Model-informed Pediatric Dosing (PI)
- 2019 Radboud Institute Health Sciences PhD Award (PI) 240,000.--
POINTeR Pediatric OrgaNoids to study Intestinal TranspoRt
- 2018 Life Sciences Health Kickstarter (PI) 75,000.--
PETIT Pediatric Intestinal Transporter (PPP with UCB Pharma)
- 2018 IMI2 Innovative Medicines Initiative 2 (Workpackage Leader) 2.630,000.--
European Pediatric Clinical Trial Network
- 2017 H2020 EPTRI (Work package leader) 123,000.--
European Paediatric Translational Research Infrastructure
- 2016 H2020 PEDCRIN (Workpackage Leader) 205,000.--
Paediatric Clinical Research Infrastructure Network
- 2016 BBMRI Innovation voucher 25,000.--
Sophia Biobank Childrens communication tool
- 2013 EU FP7 LENA (Workpackage Leader) 673,000.--
Labeling of Enalapril from Neonates up to Adolescents
- 2013 EU FP7 GAPP (Workpackage Leader) 423,000.--
GAbapentin in Paediatric Pain
- 2012 Investigator-initiated grant Novartis, Basel (PI) 500,000.--
In vitro ontogeny of drug transporters
- 2011 ZonMW Priority Medicines for Kinderen (PI) 400,000.--
Pediatric microdosing: elucidating age-related changes in oral absorption to guide dosing of new formulations
- 2011 ZonMW Priority Medicines for Kinderen (coPI) 600,000.--
Optimizing sedation in pediatric ICU patients, a nationwide study on efficacy and safety of daily interruption of sedation
- 2011 Stichting Nuts Ohra (PI) 100,000.--
Disposition and efficacy of a new rectal omeprazole formulation for gastro-esophageal reflux disease in infants
- 2010 ZonMW Clinical Fellow 165,000.--
Pharmacogenetics of tacrolimus-induced nephrotoxicity in pediatric transplant patients
- 2009 Erasmus MC Mrace Clinical Fellowship 200,000.--
Pharmacogenetics of tacrolimus-induced nephrotoxicity in pediatric transplant patients
- 2009 ZonMW Agiko (co-PI) 65,000.--
Daily sedation interruption in critically ill children PhD candidate:
Dr. N. Vet
- 2009 Erasmus MC Doelmatigheid (co-PI) 160,000.--
Daily sedation interruption in critically ill children
Other personal grants

2007 Research Training Competition (Restracomp) 28,000.--
Hospital for Sick Children, fellowship
2006 ter Meulen Fund, KNAW, research fellowship 44,000.--
Optimizing drug therapy in children: tacrolimus in pediatric transplant
2006 Research Training Competition (Restracomp) 28,000.--
Hospital for Sick Children, fellowship

Memberships American Society of Clinical Pharmacology and Therapeutics
European Society of Developmental, Perinatal and Pediatric Pharmacology
Dutch Society of Pediatrics (NVK)
Section of pediatric intensive care (SICK)
Society of Critical Care Medicine (USA)
Dutch Society of Clinical Pharmacology & Biopharmaceutics
European Society of Intensive Care Medicine/European Society of Pediatric Neonatal Intensive Care

Other Relevant Information